FACT FOCUS: Vermont ruling does not say schools can vaccinate children without parental consentWorld War III imminent, says Living Nostradamus Athos Salomé; highlights these flash points where battle could start; here's what you need to take note
How to Watch Top 25 Women’s College Basketball Games – Wednesday, December 11
Social media users described the Vermont Supreme Court’s ruling as having consequences beyond what it actually says.How to fight ageism in the world around you — and in yourself
Barclays PLC lifted its position in shares of 89bio, Inc. ( NASDAQ:ETNB – Free Report ) by 228.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 214,768 shares of the company’s stock after acquiring an additional 149,479 shares during the period. Barclays PLC owned approximately 0.20% of 89bio worth $1,590,000 as of its most recent filing with the Securities & Exchange Commission. A number of other hedge funds also recently added to or reduced their stakes in the company. Quest Partners LLC increased its holdings in shares of 89bio by 226.2% in the 2nd quarter. Quest Partners LLC now owns 8,113 shares of the company’s stock worth $65,000 after purchasing an additional 5,626 shares in the last quarter. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of 89bio during the second quarter valued at $66,000. China Universal Asset Management Co. Ltd. increased its holdings in 89bio by 76.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,370 shares of the company’s stock worth $151,000 after buying an additional 8,810 shares in the last quarter. Intech Investment Management LLC bought a new stake in 89bio in the 3rd quarter worth about $160,000. Finally, Algert Global LLC raised its position in 89bio by 30.8% in the 2nd quarter. Algert Global LLC now owns 30,587 shares of the company’s stock worth $245,000 after buying an additional 7,203 shares during the last quarter. Wall Street Analysts Forecast Growth A number of analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $29.00 price target on shares of 89bio in a report on Monday, November 11th. Cantor Fitzgerald restated an “overweight” rating and issued a $29.00 target price on shares of 89bio in a report on Friday, September 20th. Finally, Raymond James raised shares of 89bio to a “strong-buy” rating in a research report on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.33. 89bio Stock Down 1.6 % Shares of ETNB stock opened at $7.88 on Friday. The company has a current ratio of 11.66, a quick ratio of 11.66 and a debt-to-equity ratio of 0.09. 89bio, Inc. has a 12 month low of $6.43 and a 12 month high of $16.63. The stock has a market cap of $836.27 million, a P/E ratio of -2.71 and a beta of 1.12. The company has a 50 day simple moving average of $8.42 and a two-hundred day simple moving average of $8.34. Insider Activity In related news, CEO Rohan Palekar acquired 5,000 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The stock was bought at an average cost of $7.89 per share, for a total transaction of $39,450.00. Following the purchase, the chief executive officer now owns 471,236 shares in the company, valued at $3,718,052.04. The trade was a 1.07 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link . Also, Director Charles Mcwherter bought 10,000 shares of 89bio stock in a transaction that occurred on Thursday, December 5th. The stock was purchased at an average cost of $8.00 per share, with a total value of $80,000.00. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at $80,000. This represents a ∞ increase in their position. The disclosure for this purchase can be found here . Insiders acquired a total of 25,000 shares of company stock valued at $202,950 in the last 90 days. Company insiders own 2.80% of the company’s stock. 89bio Company Profile ( Free Report ) 89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. Featured Articles Five stocks we like better than 89bio The How And Why of Investing in Oil Stocks S&P 500 ETFs: Expense Ratios That Can Boost Your Long-Term Gains Are These Liquid Natural Gas Stocks Ready For An Upside Bounce? How AI Implementation Could Help MongoDB Roar Back in 2025 What is Short Interest? How to Use It Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon? Want to see what other hedge funds are holding ETNB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 89bio, Inc. ( NASDAQ:ETNB – Free Report ). Receive News & Ratings for 89bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 89bio and related companies with MarketBeat.com's FREE daily email newsletter .'I feel dodgy face fillers have scarred me for life - I don’t want to look in mirror'A number of prominent pundits, including former City defender and club ambassador Micah Richards, have questioned why the Belgium international has not been starting games amid the champions’ dramatic slump. City have not won in seven outings in all competitions – their worst run since 2008 – with De Bruyne featuring only as a substitute in the last five of those matches after recovering from a pelvic injury. The latest came with a 12-minute run-out in Sunday’s demoralising 2-0 defeat at Premier League leaders Liverpool, a result which left City 11 points off the pace and fifth in the table. Richards said on The Rest is Football podcast it appeared “there’s some sort of rift going on” between De Bruyne and Guardiola while former England striker Gary Lineker added: “It seems like all’s not well.” Former Liverpool defender Jamie Carragher said he felt “something isn’t right” and fellow Sky Sports analyst Gary Neville, the ex-Manchester United right-back, described the situation as “unusual, bizarre, strange”. Guardiola, speaking at a press conference to preview his side’s clash with Nottingham Forest, responded on Tuesday. The Spaniard said: “People say I’ve got a problem with Kevin. Do you think I like to not play with Kevin? No, I don’t want Kevin to play? “The guy who has the most talent in the final third, I don’t want it? I have a personal problem with him after nine years together? “He’s delivered to me the biggest success to this club, but he’s been five months injured (last season) and two months injured (this year). “He’s 33 years old. He needs time to find his best, like last season, step by step. He’ll try to do it and feel better. I’m desperate to have his best.” De Bruyne has not started since being forced off at half-time of City’s Champions League clash with Inter Milan on September 18, having picked up an injury in the previous game. Both the player and manager have spoken since of the pain he was in and the need to ease back into action, but his spell on the bench has been unexpectedly long. The resulting speculation has then been exacerbated because De Bruyne is in the final year of his contract but Guardiola maintains nothing untoward has occurred. He said: “I’d love to have the Kevin in his prime, 26 or 27. He would love it to – but he is not 26 or 27 any more. “He had injuries in the past, important and long ones. He is a guy who needs to be physically fit for his space and energy. You think I’m complaining? It’s normal, it’s nature. “He’s played in 10 or 11 seasons a lot of games and I know he is desperate to help us. He gives glimpses of brilliance that only he can have. “But, always I said, he himself will not solve our problems, like Erling (Haaland) won’t solve it himself. We attack and defend together. “We want the best players back. Hopefully step by step the confidence will come back and we’ll get the best of all of us.”
FACT FOCUS: Vermont ruling does not say schools can vaccinate children without parental consent
More than 1,100 small boat migrants in just three days over ChristmasNone
Abu Dhabi : An earthquake of 2.2 magnitude struck in Falaj Al Mualla area in Umm Al Quwain , United Arab Emirates (UAE) on Saturday. In a post on X, the National Centre of Meteorology (NCM) in UAE said that the quake struck at 5:51 pm UAE time, at a depth of 4km. The earthquake was not felt in the region with no effect. A 2.2 Magnitude Earthquake is recorded in Falaj Al Mualla at 17:51, 28/12/2024 "UAE time” According to the NCM “National Seismic Network” Such small earthquakes are relatively rare in the UAE. Experts at the NCM continue to monitor seismic activity in the region as part of their ongoing efforts to analyze and predict seismic events.
